

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Harry Meade et al.**

Serial No.: **09/688,254** Group No.: **1636**

Filed: **10/13/00** Examiner: **C. Qian**

For: **Method for Producing a Protein in a Transgenic Animal**

Attorney Docket Number: **GTC-43**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RECEIVED**  
AUG 12 2003  
TECH CENTER 1600/2900

**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
AFTER THE FIRST OFFICE ACTION ON THE MERITS BUT BEFORE MAILING OF  
EITHER A FINAL ACTION OR A NOTICE OF ALLOWANCE (37 CFR 1.97(c))**

**1. Authority**


Pursuant to 37 CFR § § 1.56 and 1.97-1.99, the Applicant cites to the Examiner documents containing information which, in good-faith judgment of the Applicant, may be relevant to the subject matter claimed in the above-identified application. The Applicant also encloses copies of the English-language cited documents.

In submitting this Supplemental Information Disclosure Statement, the Applicant makes no representation that a search has been performed, or the extent of any search performed, or that more relevant information does not exist.

In submitting this Supplemental Information Disclosure Statement, the Applicant makes no representation that any document cited in this Supplemental Information Disclosure Statement is, or is considered to be prior art as defined by 35 USC § § 102 and 103.

**2. Time of transmittal of accompanying Supplemental Information Disclosure Statement**

The Supplemental Information Disclosure Statement transmitted herewith is being filed

**CERTIFICATE OF MAILING BY EXPRESS MAIL**  
I hereby certify that under 37 CFR § 1.10 that this correspondence is being deposited on August 7, 2003 with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
  
Kristin Gould

09668254

0000032 502092

08/11/2003 MAHRED1

180.00 DA

03 FC:1806

*after* three months of the filing date of this national application *and after* the mailing date of the first Office action on the merits, but *before* the mailing date of either:

- (1) a final action under § 1.113, or
- (2) a notice of allowance under § 1.311, whichever occurs first.

**3. Amount of Fee**

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of a Supplemental Information Disclosure Statement under § 1.97(c).

Fee due \$ 180.00

**4. Authority to charge Deposit Account**

Please charge this fee of \$180.00 to Deposit Account No. 502092. A duplicate of this transmittal is enclosed for this purpose.


The Applicant respectfully requests that:

- a. The Examiner consider the cited information in reaching a determination concerning the patentability of the pending claims; and
- b. The enclosed Form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

Respectfully submitted,

Dated: 8/7/03

By:



Byron V. Olsen, Reg. No. 42,960  
Attorney for Applicants  
GTC Biotherapeutics, Inc.  
175 Crossing Blvd., Suite 410  
Framingham, MA 01702  
Tel. #(508) 370-5150 Fax #(508) 370-3797

AUG 07 2003

PTO/SB/08A (04-03)

Approved for use through 04/30/2003 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

<b>Application Number</b>	<b>09/688,254</b>
<b>Filing Date</b>	<b>10/13/00</b>
<b>First Named Inventor</b>	<b>Harry Meade</b>
<b>Art Unit</b>	<b>1636</b>
<b>Examiner Name</b>	<b>C. Qian</b>
<b>Attorney Docket Number</b>	<b>GTC-43</b>

<b>Sheet</b>	<b>1</b>	<b>of</b>	<b>2</b>
--------------	----------	-----------	----------

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Document Number		Date of Publication of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

RECEIVED

AUG 12 2003

TECH CENTER 1600, 2900

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)						

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/688,254
				Filing Date	10/13/00
				First Named Inventor	Harry Meade
				Group Art Unit	1636
				Examiner Name	C. Qian
Sheet	2	of	2	Attorney Docket Number	GTC-43

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Guarna et al., "Factor X fusion proteins: improved production and use in the release in vitro of biologically active hirudin from an inactive alpha-factor-hirudin fusion protein", Protein Expr Purif, 20, pgs. 133-141 (2000)	
		Richins et al., "Expression, immobilization, and enzymatic characterization of cellulose-binding domain-organophosphorus hydrolase fusion enzymes", Biotechnol Bioeng., 69 (6), pgs. 591-596 (2000)	
		Shpigel et al., "Expression, purification and applications of staphylococcal protein A fused to cellulose-binding domain", Biotechnol Appl Biochem., 31, pgs. 197-203 (2000)	

**RECEIVED**  
 AUG 12 2003  
 TECH CENTER 1600/2900

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English translation is attached.

SEND TO: Commissioner for Patents, Washington, DC 20231